Právní předpis byl sestaven k datu 15.12.2025.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx a xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 1. října 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx I - Xxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.
X xxxxx xxxxxx Přílohy X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Přílohy X Xxxxxx xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x xxxxxxx x článkem 34 odst. 3 Xxxxxx dne 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Českou xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X pro xxx 2024 x její xxxxxxx do českého xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x z. JUDr. Xxxxxx, Ph.D., LL.M., x. x.
xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;
Xxxxxxx č. 1
Překlad xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx
Xxxx
Xxxxxx zakázaných xxxxx a xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou agenturou (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.
Xxxx xxxx uvedeny xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx xxxxx a xxxxx.
Xxxxxxxx Při xxxxxxx
Xxxxx XXXX pro daný xxxxx xxxxxxxxxxx xxxx xxxxxx, je xxxxxx Xxx xxxxxxx v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 hodin) x den předcházející Xxxxxxx, xxxxx se xx Sportovec xxxxxxxxx, xx xx xxxxx Xxxxxxx a xxxxxxx xxxxxx Vzorku.
Zakázané xxxxx
Xx xxxxxxx, xx daná xxxxx nebo xxxxxx xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, xxx xx xxxxxxxxxx x Kodexu.
Specifické x Nespecifické
Podle článku 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „pro účely xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu. Žádná Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody uvedené x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx méně xxxxxxxxxx xxx xxxx dopingové xxxxx nebo metody. Xxx xxxxx x xxxxx a xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Kodexu xxxx Návykové xxxxx xxxxxxxxxx jako xxxxx, xxxxx jsou xxxx xxxxxx označeny x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve společnosti xxxx rámec xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (THC).
S0 NESCHVÁLENÉ XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu a xxxxx není x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx x xxxx (např. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx použití), xx zakázána xxxxx.
Xxxx xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Nespecifické xxxxx.
Xxxxxxxxxx xxxxx jsou zakázány.
S1.1. XXXXXXXXXX ANDROGENNÍ STEROIDY (XXX)
Xxx xxxxxxxxx podání, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion) |
• |
furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on) |
• |
mesterolon |
|
|
• |
4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion) |
• |
metandriol |
|
|
• |
7ɑ-hydroxy-DHEA |
• |
metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on) |
|
|
• |
19-norandrostenediol (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (dehydroepiandrosteron, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a další xxxxx x podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
S1.2. XXXXXXX ANABOLICKÉ LÁTKY
Mimo xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 a XX-11], xxxxxxx a xxxxxxxxxx.
X2 PEPTIDOVÉ HORMONY, XXXXXXX FAKTORY, XXXXXXXX XXXXX X XXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx jiné včetně:
S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, např. XXXX-530, xxxxxxxxxxx.
X2.1.2 Aktivační xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; molidustat (XXX 85-3934); roxadustat (FG-4592); xxxxxxxxxx (AKB-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx EPO (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX XXXXXXXXXX XXXXXXX
X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, xxxx xxxx včetně:
• choriový xxxxxxxxxxxx (CG),
• xxxxxxxxxxxx xxxxxx (XX),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx),
&xxxx;• kisspeptin x jeho agonistické xxxxxxx.
X2.2.2 Kortikotropiny a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), xxxx xxxxxxx x fragmenty, xxxx xxxx xxxxxx:
• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 x hGH 176–191.
X2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, mimo xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx a xxxxxxxxxxx,
• xxxxxxxxxxx růstového xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].
X2.3. XXXXXXX FAKTORY X MODULÁTORY XXXXXXXXX XXXXXXX
Xxxx jiné včetně:
• xxxxxxxxxxxxx xxxxxxx faktory (XXX)
• hepatocytový růstový xxxxxx (XXX)
• růstový xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, mecasermin) x xxxx analogy
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)
• xxxxxxxx-β4 x xxxx deriváty, xxxx. XX-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)
x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx látky v xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxx x neselektivní beta-2 xxxxxxxx xxxxxx všech xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 hodin;
• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 hodin.
POZNÁMKA
Přítomnost salbutamolu x moči x xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx maximální xxxxx.
X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx S4.1 x X4.2 xxxx Specifické xxxxx.
Xxxxx zařazené xx xxxx S4.3 x X4.4 jsou Nespecifické xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. INHIBITORY XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on) |
• |
formestan |
|
|
• |
4-androsten-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
|
• |
konkurenty xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx snižující xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx aktivinu (xxxx. XXX-031) |
- proteiny xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. bimagrumab) |
- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) kyselina xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , např. XX9009, XX9011
X4.4.2 insuliny a xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 DIURETIKA X XXXXXXXXX LÁTKY
ZAKÁZANÉ XXXXX (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx xxxxx jsou Specifické xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. d- x x-, xxxx xxxxxxxx.
Xxxx xxxx včetně:
• Diuretika, xxxx např.:
acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;
• Vaptany, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;
• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, xxxx.:
xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx a pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo případně Xxx Xxxxxxx ve xxxxxxx s diuretikem xxxx xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (AAF), xxxxx Sportovec nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, která již xxxx xxxxxxx xx xxxxxxxxxx nebo jinou xxxxxxxxx xxxxx.
XXXXXXXX METODY
ZAKÁZANÉ XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx x výjimkou xxxxx x X2.2, xxx jsou Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X KREVNÍMI XXXXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx krvinek jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx s výjimkou xxxxxxxx plazmy xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.
X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu nebo xxxxxxx kyslíku.
Mimo xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; efaproxiral (RSR13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.
M1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx manipulace x krví nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX A XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Podvádění xxxx Xxxxx o xxxxxx xx účelem xxxxxxx xxxxxxxxx a platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.
Mimo jiné xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx ke Vzorku.
M2.2. Xxxxxxxxxx infuze a/nebo xxxxxxx xxxx než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. XXXXXX X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
M3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, xxxxx xxxxx změnit xxxxxxxx xxxxxx a/nebo exprese xxxx xxxxxxxxxx mechanismem. Xx xxxx xxxx xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Specifické látky x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxx látky x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)
Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.
Xxxxxxxxxxx zahrnují:
S6.A: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.
X6.X: SPECIFICKÁ XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxx (xxxxxxxxx) |
• |
xxxxxxxxxxx x jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx xxxxxxx, např. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx imidazolinu v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xylometazolin) x xxxxxxxxxxx zařazená xx Monitorovacího xxxxxxxx 20245).
X7 NARKOTIKA
ZAKÁZANÉ PŘI XXXXXXX
Xxxxxxx zakázané látky x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxxx xxxxx v této xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. d- x x, jsou xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové látky x této xxxxx: xxxxxxxxxxxxxxxxxxx (THC)
Všechny přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, např.
• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• přírodní x xxxxxxxxxx tetrahydrokanabionoly (XXX)
• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx jakoukoliv xxxxxxxx, perorální [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx acetonid |
||
|
• |
kortizon |
• |
hydrokortizon |
||||
|
• |
deflazakort |
• |
metylprednisolon |
POZNÁMKA
• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx se xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X URČITÝCH XXXXXXXX
Xxxxxxx xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx sportech Při Xxxxxxx a kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.
• lukostřelba (XX)*
• lyžování/snowboarding (FIS) – xxxxx na xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx a xxxxxxxxx X-xxxxx / xxx xxx
• xxxxxxxxxxxx xxxxx (XXX)
• podvodní xxxxxx (CMAS)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (WDF)
• xxxx (XXX)
• minigolf (XXX)
• xxxxxxx (XXXX, XXX)*
* xxxxxxxx xxxx Xxxx xxxxxx
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) katin (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx koncentraci x moči vyšší xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx pouze xxx koncentraci x xxxx xxxxx než 150 xxxxxxxxxx v 1 xx.
3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml.
4) xxxxxxxxx (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, např. xxxxx, oční, nebo xxxxxxxx podávání x xxxxxxxxx xxxxxxxxxx.
5) bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 19/2025 Xx. nabyl xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx